TY - JOUR
T1 - Lymphoma models for B cell activation and tolerance IV. Growth inhibition by anti‐Ig of CH31 and CH33 B lymphoma cells
AU - Pennell, Christopher A.
AU - Scott, David W.
PY - 1986
Y1 - 1986
N2 - CH31 and CH33 are B cell lymphomas whose growth in vitro is inhibited by anti‐Ig reagents, including both polyclonal and monoclonal anti‐μ antibodies, and an anti‐idiotype antiserum. Antibodies against class I or class II major histocompatibility complex antigens do not affect the growth of these cells. Inhibition is dependent on surface Ig cross‐linking and does not require ligand binding to Fc receptors. Interestingly, the inhibition of growth by anti‐μ, is reversed in CH31 (but not CH33) by E. coli lipopolysaccharide. These lymphomas should provide excellent models to study the mechanisms of growth inhibition mediated by surface Ig cross‐linking and the pathways of its reversal.
AB - CH31 and CH33 are B cell lymphomas whose growth in vitro is inhibited by anti‐Ig reagents, including both polyclonal and monoclonal anti‐μ antibodies, and an anti‐idiotype antiserum. Antibodies against class I or class II major histocompatibility complex antigens do not affect the growth of these cells. Inhibition is dependent on surface Ig cross‐linking and does not require ligand binding to Fc receptors. Interestingly, the inhibition of growth by anti‐μ, is reversed in CH31 (but not CH33) by E. coli lipopolysaccharide. These lymphomas should provide excellent models to study the mechanisms of growth inhibition mediated by surface Ig cross‐linking and the pathways of its reversal.
UR - http://www.scopus.com/inward/record.url?scp=0022881639&partnerID=8YFLogxK
U2 - 10.1002/eji.1830161217
DO - 10.1002/eji.1830161217
M3 - Article
C2 - 3493148
AN - SCOPUS:0022881639
SN - 0014-2980
VL - 16
SP - 1577
EP - 1581
JO - European Journal of Immunology
JF - European Journal of Immunology
IS - 12
ER -